**Background**
Oxidative stress and mitochondrial dysfunction are central drivers in the pathogenesis of various organ injuries, including cardiotoxicity, neurodegeneration, and diabetic nephropathy. The accumulation of reactive oxygen species (ROS) often triggers apoptotic and necroptotic pathways, leading to irreversible tissue damage. Protecting these vital organs requires the activation of endogenous antioxidant defenses and the stabilization of mitochondrial membrane potential. Among the endogenous metabolites that regulate energy homeostasis and cellular protection, phosphocreatine plays a critical role in maintaining ATP levels and mitigating oxidative damage. In this context, we will introduce a high-purity endogenous metabolite – Phosphocreatine disodium.
**Definition**
Phosphocreatine disodium is an organic compound and endogenous metabolite found in vertebrate skeletal muscles that acts as a potent antioxidant and cytoprotective agent. According to the Phosphocreatine disodium description, it functions by enhancing antioxidant activity and activating key survival pathways, such as TAK1 and Nrf2/HO-1, to protect the heart, brain, and kidneys.
**In Vitro and In Vivo Studies**
The Phosphocreatine disodium biological activity has been extensively validated across multiple cell lines and animal models. In vitro, Phosphocreatine (0-1 mM, 24 h) protects H9c2 cardiomyocytes against doxorubicin-induced injury by targeting TAK1 and reducing necroptosis. In PC-12 cells, concentrations of 5-20 mM (2-24 h) attenuate methylglyoxal (MGO)-induced apoptosis and prevent the loss of mitochondrial membrane permeability via the Akt-mediated Nrf2/HO-1 pathway. Furthermore, in NRK-52E cells, concentrations of 5-40 mM (24 h) protect against MGO-induced kidney injury by increasing Bcl-2 and procaspase-9 expression while decreasing Bax and cleaved caspase-3 levels.
Phosphocreatine disodium in vivo studies further demonstrate its therapeutic potential. In rats with doxorubicin-induced cardiotoxicity, administration of phosphocreatine (200 mg/kg, i.p., once every other day for 7 weeks) improved heart function, lowered myocardial apoptosis, and recovered the expression of Nrf2 and SOD. In SD rats with streptozotocin-induced diabetic nephropathy, phosphocreatine (20-40 mg/kg, i.v., daily for 6 weeks) reduced hyperglycemia, decreased the kidney weight index, and lowered MDA levels while increasing GSH and SOD levels. In conclusion, Phosphocreatine disodium is a versatile cytoprotective agent that mitigates oxidative stress and apoptosis across multiple organ systems.
Keywords
Phosphocreatine disodium, 922-32-7, Disodium creatine, Endogenous Metabolite, MAP3K, Akt, Mitochondrial Metabolism, ERK, Apoptosis, ROS Kinase, MAP kinase kinase kinase, MEKK, MAPKKK, PKB, Protein kinase B, Extracellular signal regulated kinases, ATP
References
[1] Feldman EB, et al. Creatine: a dietary supplement and ergogenic aid. Nutr Rev. 1999 Feb;57(2):45-50.
[2] Wang C, et al. Phosphocreatine attenuates doxorubicin-induced cardiotoxicity by inhibiting oxidative stress and activating TAK1 to promote myocardial survival in vivo and in vitro. Toxicology. 2021 Aug;460:152881.
[3] Li H, et al. Neuroprotective effect of phosphocreatine on oxidative stress and mitochondrial dysfunction induced apoptosis in vitro and in vivo: Involvement of dual PI3K/Akt and Nrf2/HO-1 pathways. Free Radic Biol Med. 2018 May 20;120:228-238.
[4] Shopit A, et al. Protection of diabetes-induced kidney injury by phosphocreatine via the regulation of ERK/Nrf2/HO-1 signaling pathway. Life Sci. 2020 Feb 1;242:117248.